VORINOSTAT

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndromes

Conditions

Myelodysplastic Syndromes

Trial Timeline

May 1, 2008 → Nov 1, 2011

NCT ID

NCT00776503

About VORINOSTAT

VORINOSTAT is a phase 1/2 stage product being developed by Merck for Myelodysplastic Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT00776503. Target conditions include Myelodysplastic Syndromes.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01365065	Phase 2	UNKNOWN	May 1, 2011	Jan 1, 2018	HIV Positive
NCT01319383	Phase 1/2	Completed	Feb 1, 2011	Mar 31, 2016	HIV-1 Infection
NCT00918489	Phase 2	Completed	May 1, 2010	Sep 1, 2013	Soft Tissue Sarcoma
NCT01000155	Phase 2	Terminated	Oct 1, 2009	Oct 1, 2014	Sickle Cell Disease
NCT00821951	Phase 1	Completed	May 1, 2009	Jul 1, 2012	Non-Small Cell Lung Cancer (NSCLC)
NCT00831493	Phase 1/2	Terminated	May 1, 2009	Oct 1, 2010	Pancreatic Cancer
NCT00875056	Phase 2	Completed	Apr 15, 2009	Feb 8, 2019	Lymphoma
NCT00735826	Pre-clinical	Completed	Mar 1, 2009	Jul 1, 2012	Aerodigestive Tract Cancer
NCT00838929	Phase 1	Completed	Mar 1, 2009	Mar 1, 2015	Brain Metastases
NCT00719875	Phase 1	Completed	Dec 1, 2008	Jun 1, 2013	Advanced Breast Cancer
NCT00771472	Phase 1	Completed	Aug 1, 2008	Jul 1, 2011	Lymphoma
NCT00776503	Phase 1/2	Completed	May 1, 2008	Nov 1, 2011	Myelodysplastic Syndromes
NCT00561418	Phase 1	Completed	Nov 1, 2007	May 1, 2013	Lymphoma
NCT00416130	Phase 1/2	UNKNOWN	Jan 1, 2007	Jan 1, 2015	Breast Cancer
NCT00907738	Phase 2	Completed	Aug 1, 2005	Jun 1, 2010	Advanced Cancer
NCT00127127	Phase 1	Completed	Jun 10, 2005	Aug 21, 2009	Tumors
NCT00127140	Phase 1	Completed	Jun 1, 2005	Apr 1, 2012	Lymphoma

Competing Products

20 competing products in Myelodysplastic Syndromes

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	28
JSP191	Jasper Therapeutics	Phase 1	25
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	25
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	33
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	52
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	52
Decitabine + Valproic Acid	Eisai	Phase 2	52
decitabine + decitabine	Eisai	Phase 2	52
decitabine + azacitidine	Eisai	Approved	85
Decitabine	Eisai	Phase 2	52
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	33
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	52
Subcutaneous Decitabine	Eisai	Phase 1	33
Decitabine	Eisai	Phase 2	52
Galunisertib + Placebo	Eli Lilly	Phase 2/3	65
DSP-7888	Sumitomo Pharma	Phase 1/2	41
TP-0184	Sumitomo Pharma	Phase 1/2	41
Decitabine	Johnson & Johnson	Phase 2	52
Epoetin alfa	Johnson & Johnson	Phase 2	52
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	52

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved